Trial Details
RECRUITINGBasic Information
| Clinical ID | c452 |
|---|---|
| Identifier | NCT06598943 |
| Trial Title | A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis |
| Trial URL | Visit Original Page |
Study Information
| Study Results | NO |
|---|---|
| Conditions | Ulcerative Colitis|Ulcerative Colitis Chronic |
| Interventions | DRUG: Eltrekibart|DRUG: Mirikizumab|DRUG: Placebo |
Participant Information
| Sponsor | Eli Lilly and Company |
|---|---|
| City | Chandler |
| Country/Region | United States |
Enrollment Criteria
| Sex Requirement | ALL |
|---|---|
| Age Requirement | ADULT, OLDER_ADULT |
Study Design
| Study Type | INTERVENTIONAL |
|---|---|
| Phase | PHASE2 |
Time Information
| Start Date | 2024-10-10 |
|---|---|
| Primary Completion Date | 2027-12 |
| Completion Date | 2028-09 |